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Abstract
Secreted factors and cell surface receptors can be internalized by endocytosis and translocated to
the cytoplasm. Instead of being recycled or proteolysed, they sometimes translocate to the nucleus.
Nuclear import generally involves a nuclear localization signal contained either in the secreted
factor or its transmembrane receptor, that is recognized by the importins machinery. In the
nucleus, these molecules regulate transcription of specific target genes by direct binding to
transcription factors or general coregulators. In addition to the transcription regulation, nuclear
secreted proteins and receptors seem to be involved in other important processes for cell life and
cellular integrity such as DNA replication, DNA repair and RNA metabolism.
Nuclear secreted proteins and transmembrane receptors now appear to induce new signaling
pathways to regulate cell proliferation and differentiation. Their nuclear localization is often
transient, appearing only during certain phases of the cell cycle. Nuclear secreted and
transmembrane molecules regulate the proliferation and differentiation of a large panel of cell types
during embryogenesis and adulthood and are also potentially involved in wound healing. Secreted
factors such as CCN proteins, EGF, FGFs and their receptors are often detected in the nucleus of
cancer cells. Nuclear localization of these molecules has been correlated with tumor progression
and poor prognosis for patient survival. Nuclear growth factors and receptors may be responsible
for resistance to radiotherapy.
Background
The classical view of the way secreted molecules such as
growth factors and protein hormones operated was that
they acted at the cell surface by binding membrane recep-
tors and activating cascades of intracellular second mes-
sengers, leading to the regulation of expression of specific
target genes. Their internalization in endosomal vesicles
and degradation in lysosomal compartment was seen as a
way to stop their activation (For further details, see review
[1]). But some evidence showed that their modes of
action seem to be more complex. An unexpected finding
was that internalized Fibroblast Growth Factors (FGFs)
can have a long life inside the cell (over 24 hours), and it
has been shown that several FGFs such as FGF1, FGF2 and
FGF3 can act both extracellularly and intracellularly.
Nuclear localization of FGFs and Epidermal Growth Fac-
tor (EGF) and of their cell surface receptors (FGFRs and
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EGFR respectively) has been well documented over the
last 15 years in normal and physiopathological states. The
deciphering of the underlying mechanisms of such appar-
ently unexpected subcellular localization revealed that
secreted factors and their receptors were internalized into
the cytoplasm and routed to the nucleus, where they exert
diverse functions such as regulation of gene transcription.
By modulating the expression of genes involved in cell
cycle progression, nuclear forms of growth factors (GFs)
and of their surface tyrosine-kinase receptors (RTKs) often
regulate cell proliferation. Other RTKs such as Vascular
Endothelial Growth Factor (VEGF) and Nerve Growth
Factor receptors have also been detected in the cell
nucleus. Several lines of data also reported nuclear traf-
ficking for a variety of other classes of secreted molecules
such as interleukines and hormones. For instance, Inter-
leukin-1 (IL-1), IL-5, Interferon-γ (IFNγ), Growth Hor-
mone (GH), Prolactin, Lactoferrin, Insulin-Like Growth
Factor Binding Proteins (IGFBPs) have been detected in
the cell nucleus (reviewed in [2]).
The number of secreted proteins concerned by nuclear
trafficking is growing. Emerging data on members of the
CCN family enlarge the circle of secreted factors that are
involved in this phenomenon [3-5]. The CCN proteins are
secreted factors that act as key regulators in embryonic
development, and are associated with severe pathologies
including fibrotic diseases and cancers [6-12]. Acting on
cell adhesion, migration, proliferation, differentiation
and survival, they regulate fundamental cell processes of
fetal and adult life, such as angiogenesis, skeletal develop-
ment, wound repair and inflammation. The CCN family
is composed of 6 members in human, which have been
grouped on the basis of structural analogies. The CCN
proteins are indeed composed of four structural modules
that contain regions homologous to sequences found in
IGFBPs, Thrombospondin and Von Willebrand Factor
(Figure 3A). The carboxy-terminal domain (CT) contains
cysteine residues that could form a cystine knot.
The mechanisms of transport from the extracellular com-
partment to the cell nucleus is well understood for FGFs,
EGF and their RTKs. By contrast, transportation to the
nucleus of the other secreted molecules is still largely
unknown. Secreted and transmembrane proteins are gen-
erally internalized by endocytosis, delivered in the cyto-
plasm, and then transported to the nucleus by classical
pathways involving specific proteins (importins) that rec-
ognize nuclear localization signals (NLS) in cargo pro-
teins. This current review will not cover in detail the
nucleocytoplasmic shuttling mechanisms since the recent
literature presents detailed reviews about this aspect [13-
15]. Instead, we will focus on nuclear functions of
secreted proteins and cell surface receptors in normal and
pathophysiological states.
Nuclear shuttling
Internalization from the plasma membrane
When reports started to appear on the nuclear localization
of GFs and surface receptors, one of the first questions
addressed was to determine if these molecules came from
the cell surface after internalization or if they were alterna-
tive intracellular forms lacking the signal peptide of secre-
tion. Intact, full-length molecules have been found in the
nucleus. According to the current literature, it has become
clear that nuclear cell-surface receptors and ligands often
come from the cell surface. Macromolecules can be inter-
nalized by two major endocytic pathways, involving
either caveolin or clathrin.
FGF growth factors not only activate transmembrane
receptors but may also be co-internalized with their recep-
tors in the cytoplasm and translocated to the nucleus.
FGFs bind to 4 transmembrane receptors (FGFR1–4)
expressed in a tissue-specific manner. Several approaches
using elegant methods revealed recently that nuclear
FGFRs and FGF1 and FGF2 are first internalized from the
cell surface by endocytosis. These processes seem to be
clathrin-independent, but may involve lipid/caveolin
dependent mechanisms. Furthermore, delivery of exoge-
nous FGFs from intracellular vesicles into cytoplasm
requires establishment of an electrical potential across
vesicular membrane, involving proton pump and Na+/K+
– ATPase [16,17]. These processes have recently been
reviewed [1,2,18]. PI3 kinase activity is required for trans-
location of FGF1 and FGF2 across the endosomal mem-
brane [17], as well as Heat Shock Protein-90 (Hsp90)
[19]. Interestingly, transport of FGF1 and FGF2 across
endosomal membranes seems to be most efficient during
the G1 phase of the cell cycle [17].
The use of labeled EGF showed that nuclear EGF was
derived from extracellular added ligand. EGFR belongs to
the ErbB family of transmembrane tyrosine-kinase recep-
tors, which encompasses four structurally members
(ErbB1–4) also known as HER. ErbB/HER receptors bind
specific secreted molecules, with the exception of ErbB2
(a.k.a. Neu), that has no obvious ligand. EGFR and ErbB2/
HER-2 are translocated from the cell surface to the nucleus
through endocytosis [20,21]. Blocking EGFR endocytosis
suppresses its nuclear import [22], and EGFR nuclear
shuttling is dependent on EGF stimulation.
IGFBP2, IGFBP3 and IGFBP5 have been detected in the
cell nucleus. Furthermore, nuclear import of endogenous
IGFBP3 was shown to require IGFBP3 secretion and re-
uptake. Endocytosis of extracellular IGFBP3 is mediated
by caveolin-pathway and a clathrin-pathway specific to
transferrin/transferrin receptor [23].Cell Communication and Signaling 2006, 4:7 http://www.biosignaling.com/content/4/1/7
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Externally added CCN2 recombinant protein has been
A NLS is located in the CT domain of the CCN3 protein Figure 1
A NLS is located in the CT domain of the CCN3 protein. A) Conservation of the primary structure of this Arg/Lys-
rich NLS in the human CCN proteins at the beginning of CT module. Basic amino acids are colored in red and marked with an 
asterisk in the human CCN3 sequence. These Arginine and Lysine residues are colored in blue when they are not conserved in 
the other CCN proteins. Replacement of a basic residue by another is represented in orange. Other non-conserved amino 
acids are colored in grey. B) Human G59 glioblastoma cells transiently transfected with GFP-NLS constructs. C) Baby Ham-
ster Kidney 21 (BHK21) cells transiently transfected with CCN3 constructs (similar strategy of construction as the one 
described in [5]. GFP and DAPI autofluorescence were detected with epifluorescence under appropriate filters. CCN3 was 
detected by immunostaining with K19M antibodies [122].
B)
A)
NLS:PTDKKGKKCLRTKKSLKA
NLSΔ Δ Δ Δ1:PTDKKGK
C)
NLS C N GFP
Δ Δ Δ ΔCCN3 C N
Δ Δ Δ ΔCCN3 C N SP
NLSΔ Δ Δ Δ1 Dapi Dapi
GFP Dapi Dapi NLS
GFP
Δ Δ Δ ΔCCN3 SP-Δ Δ Δ ΔCCN3
CCN3: PTDKK GKKCLRTKKSLKA
CCN2:  NIKK GKKCIRTPKISKP
CCN1:  SLKK GKKCSKTKKSPEP
CCN4:  LIK AGKKCLAVYQPEAS
CCN6:  TIKIPKGKTCQPTFQLSKA
** * * * * * *Cell Communication and Signaling 2006, 4:7 http://www.biosignaling.com/content/4/1/7
Page 4 of 18
(page number not for citation purposes)
found to enter the cell and localize in the perinuclear
compartment [4]. CCN proteins physically interact with
several classes of cell-surface proteins such as integrins,
Heparan Sulfate Proteoglycans (HSPGs), Notch and con-
nexins. Though a CCN2-binding protein has been identi-
fied in the plasma membrane of HCS-2/8 chondrocytes,
definitive clues about the existence of transmembrane
receptors specific to CCN proteins are still lacking to date.
The mechanism of cell entry is completely unknown.
Translocation to the nucleus
Nuclear import via classical NLS pathways seems to be a
general feature for secreted factors and their receptors.
Briefly, small molecules (size of less than 40 kDa) can dif-
fuse freely through the nuclear pores, but nuclear import
generally implicates basic amino-acids-rich NLS
sequences, which are recognized by carrier proteins of the
importin (IMP) family. The prototypic carrier consists of
2 importin sub-units: IMPα, that contacts the NLSs in the
cargo proteins that have to be imported to the nucleus,
and IMPβ1, that binds to hybrophobic repeat sequences
in nucleoporins proteins (Nups), that constitute the
nuclear pore complexes (NPCs). Some cargo proteins can
be transported to the nucleus by IMPβ1 alone. For further
details on nuclear shuttling, see reviews by [13-15].
The nuclear import of IGFBP3 and IGFBP5 is dependent
on a NLS pathway mediated by IMP-β [24]. The Parathy-
roid Hormone-related Protein (PTHrP), a secreted protein
that is related to the parathyroid hormone, a major regu-
lator of calcium homeostasis, also contains a NLS. Several
types of NLS can be found in FGFs molecules. FGF1 and
FGF2 present different isoforms of low and high molecu-
lar weight (LMW and HMW respectively), resulting from
Summary of the diverse pathways of nuclear shuttling and nuclear functions of secreted proteins and cell surface receptors Figure 2
Summary of the diverse pathways of nuclear shuttling and nuclear functions of secreted proteins and cell sur-
face receptors. Trf: transferrin; Imp: importin; Exp: exportin; RNA PolII: RNA polymeraseII; (Ub)n: polyubiquitination; Splic: 
splicing machinery; UBS: upstream factor binding site; FT: transcription factor (For nuclear EGFR, the E2F1 and STAT3 tran-
scription factors were identified as binding partners).
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A transactivation domain is located in the VWC module of the CCN3 protein Figure 3
A transactivation domain is located in the VWC module of the CCN3 protein. A) Nomenclature and schematic 
depicting of the modular structure of the CCN3 protein. IGFBP: Insulin Like Growth Factor Binding Protein-like module; 
VWC: Von Willebrand factor-like module; TSP1: Thrombospondin-like module; CT: C-terminal module. Acidic residues are 
colored in blue, proline in red, and are marked by an asterisk in the human CCN3 VWC module. B) The pGBT9 transfectants 
(Gal4DBD fusion proteins) were selected and grown in minimal medium deprived of tryptophane. The Y190 recipient yeast 
used in this experiment contains a recombinant lacZ reporter gene cloned downstream a promoter containing upstream Gal4 
DBD binding sites (activator binding sites). Qualitative assays were performed on Whatman filter paper. The β-galactosidase 
activity was monitored every half hour for a total period of 8 hours. C) Upper panel: diagram depicting the mammalian 
reporter system used in this study (pFA/pFR-Luc, Stratagen). Lower panel left: Immunocytofluorescent detection of Gal4DBD-
NH3 protein in transiently transfected BHK21 cells, showing nuclear localization of the fusion protein using anti-His antibody 
(protocol for immunodetection described in [5]). Lower panel right: BHK21 cells were co-transfected with 1 μg of pFR-Luc 
and increasing amounts of NH3. The total amount of DNA used for each transfection was kept constant by adjustment with 
pFA DNA. BHK21 (baby hamster kidney 21) cells were grown and transfected as decribed in [5]. Posttranfection (48 h), luci-
ferase and β-galactosidase activity from cell lysates was measured as described in [5].
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alternative translation initiation. LMW FGFs are secreted
and need to be re-internalized to be routed to the nucleus.
In contrast to LMW isoforms, HMW forms (21–34 kDa)
are not excreted from the cell and are routed to the
nucleus directly from the cytoplasm. Both LMW and
HMW FGFs contain one or several NLSs. For instance, a
secreted form of FGF1, that does not contain a classical
signal peptide of secretion, possesses two NLS: one
located in its amino-terminal part and the other, a non-
conventional bipartite NLS, in its carboxyterminal
extremity [25]. Both are important for efficient transport
of FGF1 to the nucleus. LMW FGF2 contains a signal pep-
tide for secretion and also shows a non classical bipartite
NLS in its C-terminal part [26,27]. Stimulation of FGFR1
by FGF1 and FGF2 results in the nuclear translocation of
FGFR1 in an IMP-β dependent manner [2,28]. HMW FGFs
show an Arginine-rich NLS-like in their aminoterminal
extension. Along the same lines, a subfamily of FGF pro-
teins, FGF11–14, named FHFs (for FGF Homology Fac-
tors) are devoid of signal peptide but contain a sequence
rich in basic amino acids that resemble a NLS. They are
not secreted. FGF11 was even shown to accumulate in the
nucleus in NLS-dependent manner (reviewed in [1]).
FGF3 constitutes an interesting case. A duality between
secretion and nuclear import has indeed been reported for
this growth factor. FGF3 contains three polycationic
sequences that are important for nuclear localization. The
first one is a bipartite NLS located in the amino-terminal
part of FGF3, and the other two were found in the car-
boxy-part of the molecule. These NLS exert additive effects
in counteracting the signal peptide [29,30]. Secreted and
nuclear forms of FGF3 exhibit opposite effects on cell pro-
liferation.
An amino-truncated form of CCN3 devoid of signal pep-
tide has been detected in the nucleus of cancer cells
([3,31,32] and unpublished data). The CCN3 protein was
recently shown in our laboratory to contain a NLS that tar-
gets intracellular forms devoid of signal peptide to the
nucleus [5]. CCN3 NLS is a polycationic sequence rich in
lysine (PTDKKGKKCLRTKKSLKA) located at the begin-
ning of the CT module. This NLS is sufficient to drive the
Green Fluorescent Protein (GFP) to the nucleus ([5] and
Figure 1B). These observations suggest that CCN3 forms
are transported to the nucleus via importins pathway. It is
worth noting that the PTDKKGK sequence does not seem
to be able to drive GFP to the nucleus (Figure 1B), though
it has been identified as a NLS, using a bioinformatic
approach (PSORT II server: [33]). The CCN3 signal pep-
tide seems to be dominant on the NLS. Forms that contain
both the signal peptide and the NLS are localized at the
cell surface ([5] and Figure 1C). An amino-truncated
CCN3 protein has been found in the supernatant of cell
producing the full length secreted form of CCN3 [34]. The
most attractive hypothesis about the generation of nuclear
truncated forms of CCN3 is that, after secretion of the full-
length protein and cleavage in the extracellular compart-
ment, the carboxy-terminal part of the protein could re-
enter the cell and be routed to the nucleus via an NLS-
dependent pathway [5,7]. The basic amino-acids of the
CCN3 NLS are highly conserved in CCN2 and CCN1 (Fig-
ure 1A). This NLS sequence may therefore be responsible
for nuclear transport of exogenous CCN2 after internali-
zation from plasma membrane. Along the same line,
CCN1 forms may also be routed to the nucleus, though
no evidence is documented in the current literature. By
contrast, the poor conservation of this Arg/Lys-rich
sequence in CCN4 and CCN6 suggest that these two pro-
teins would not be routed to the nucleus, or at least not by
this mechanism.
IFNγ contains a prototypic NLS. Mutations in the IFNγ
NLS abolish its biological activities. Endocytosed IFNγ
binds to IMPα5, suggesting a nuclear import via the
IMPα/β1 dependent pathway. The α-subunit of the het-
erodimeric IFNγ receptor (IFNGR-1) also translocates to
the nucleus in IFNγ-treated cells. After internalization by
endocytosis, IFNγ/IFNGR-1 complexes are translocated to
the nucleus in association with Signal Transducer and
Activator of Transcription-1a (STAT1a). STATs are tran-
scription factors activated by a large panel of secreted pro-
teins (cytokines, hormones, etc). Inactive STATs are
localized in the cytoplasm and translocate to the nucleus
after phosphorylation by a RTK. STAT1a is able to directly
contact IMPα5 via an unconventional NLS that exhibits a
much lower affinity for importins than conventional
NLSs. These observations lead Johnson and his col-
leagues, in a recent review [13], to propose an attractive
hypothesis whereby the nuclear transport of the IFNγ/
IFNGR-1 complex brings STAT1a into the nucleus and
allows IFNγ-specific responses by a downstream effector,
that is besides being activated by plethora of secreted fac-
tors.
In contrast to the above quoted examples, PRL lacks a NLS
sequence, and its nuclear translocation requires the pres-
ence of its receptor at the plasma membrane [35,36]. The
Cyclophilin B protein (CypB), that contains a putative
NLS, has been proposed to transport PRL to the nucleus
[37]. Related to PRL, GH exhibits exactly an inverse situa-
tion. Indeed, GH, its cell surface receptor (GHR) and a
related protein (GHBP) that binds GH have been found in
the nucleus but this time, nuclear translocation of GHR
and GHBP requires GH stimulation.
Similar to PRL, EGF does not contain an intrinsic NLS and
its nuclear localization is dependent on expression of sur-
face EGFR, that has a polycationic NLS. EGFR interacts
with IMPα1/IMPβ1 [22]. Binding of EGF to nuclear EGFRCell Communication and Signaling 2006, 4:7 http://www.biosignaling.com/content/4/1/7
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results in autophosphorylation of EGFR and phosphor-
ylation of other nuclear proteins (reviewed in [13]).
Intriguingly, the Schwannoma-derived Growth Factor
(SwGF), another ligand for EGFR, does contain a NLS.
Other RTKs of the EGFR/ErbB family are also found in the
nucleus. For instance, ErbB2 is driven to the nucleus in an
IMPβ-dependent pathway [21]. ErbB4/HER4 contains
three potential polycationic NLS in its carboxy-terminal
part, but only one of them was shown to drive the GFP
protein to the nucleus ([38]. Of note, nuclear forms of
Erb4/HER4 do not come from internalization of the trans-
membrane form by endocytosis. Instead, transmembrane
Erb4/HER4 is cleaved by the metalloproteinase γ-secretase
at the plasma membrane, releasing its cytoplasmic tail
which is translocated to the nucleus [39,40].
All the above examples depict the diversity of situations in
which secreted proteins and their cell surface receptors are
internalized from the plasma membrane or directly
routed to the nucleus from the cytoplasm. A summary of
the various cases is presented in Figure 2. Once they have
acted in the nucleus, secreted and cell-surface molecules
have to be inactivated.
Export from the nucleus and inactivation in the nucleus
The regulation of the nuclear functions of these proteins
begins to be deciphered. Nuclear activities of GFs can be
regulated by export from the nucleus to the cytoplasm.
Recent reports indeed showed that the nucleocytoplasmic
shuttling of these proteins involves classical nuclear
export pathways (review on nuclear export mechanisms in
[15]). Active nuclear export generally implicates a leucine-
rich nuclear export signal (NES) in the cargo proteins. This
NES is recognized by exportin (EXP) proteins, which
allow nuclear pore crossing.
ErbB4/HER4 contains such an NES. Nuclear export of
EGFR, ErbB2/HER2 and PTHrP is blocked by leptomycin
B, an inhibitor of CRM1/EXP-1 protein [21,22,41], sug-
gesting that they are also exported by NES pathways. A
phosphorylation process regulates nucleocytoplasmic
shuttling of FGF1. Externally added FGF1 is phosphor-
ylated in the nucleus by PKCδ and subsequently rapidly
exported to the cytoplasm, in a manner that is inhibited
by leptomycin B, then dephosphorylated and probably
degraded in the cytoplasm [42]. Non phosphorylated
FGF1 remains in the nucleus. FGF1 does not contain an
obvious NES. It is therefore possible that it is exported
from the nucleus by binding to a partner that possesses a
NES (Summary in Figure 2).
Alternatively, some nuclear secreted proteins and trans-
membrane RTKs may be inactivated inside the nucleus by
proteolysis, as suggested by the recent discovery of ubiq-
uitin/proteasome-mediated degradation of nuclear
IGFBP3 [43] (Figure 2).
Regulation of gene transcription and other 
nuclear functions
According to the current literature, it appears that nuclear
secreted factors and RTKs generally regulate gene tran-
scription. Though initial studies depicted binding of
nuclear RTKs and GFs to DNA, no structural DBD has ever
been characterized in these molecules. Therefore, it is
likely that they do not directly bind DNA, but rather inter-
act with DNA binding partners, and that their transcrip-
tional activity depends on interactions with other
transcription factors such as specific transcription factors
and general co-regulators. Recent studies also revealed
potential roles in other nuclear processes such as DNA
repair and RNA processing.
Interaction with transcriptional regulators
EGFR and EGF were initially shown to bind chromatin,
and SwGF, to AT-rich DNA sequences [44,45]. We now
know that some nuclear RTKs of the EGFR/ErbB family
specifically bind target promoters. For instance, nuclear
EGFR binds to AT-rich sequences in the promoter of the
Cyclin D1 gene and activates its transcription [46]. Like-
wise, ErbB2/HER2 binds to a specific sequence called HAS
(HER2 associated sequence). The promoters of the
Cyclooxygenase2 (COX2), PRPK, MMP16 and DDX10 genes
were identified as direct target promoters of nuclear ErbB2
[47]. It is worth noting that positive correlations have
been established between nuclear localization of EGFR/
ErbB receptors and expression levels of target genes in
tumors (see below), underlining the pathophysiological
relevance of these results. Nuclear EGFR complexes with
STAT3 and co-regulates transcription of the iNOS gene
[48]. In a similar manner, its interaction with E2F1 acti-
vates the expression of the b-Myb gene, which encodes an
essential transcription factor for cell cycle progression
[49]. EGFR-E2F1 association with the b-Myb promoter is
only detected during the G1/S phase transition [49]. Inter-
estingly, inhibition of major EGFR downstream pathways
such as PI-3K and ERK does not significantly suppress the
EGFR-induced b-Myb expression [49]. Similar to nuclear
EGFR, ErbB4/HER4 co-activates the expression of the β-
casein gene by binding STAT5a [38]. ErbB4 may therefore
potentiate the expression of milk genes by STAT5a during
pregnancy and lactation. Similarly, nuclear PRL-CypB and
GHBP potentiate STAT5 transcriptional activities [37,50].
As for the EGF/ErbBs family, members of the FGFs/FGFRs
family regulate the transcription of specific target gene by
interacting with various nuclear partners. FGFR1 tran-
scriptional activities were suggested when immunoelec-
tron microscopic, and confocal analysis revealed that
FGFR1 co-localized with transcriptionally active chroma-Cell Communication and Signaling 2006, 4:7 http://www.biosignaling.com/content/4/1/7
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tin [51]. FGFR1 binds to the general co-activator CREB-
binding protein (CBP) and up-regulates the expression of
specific target genes such as FGF2 and Tyrosine Hydroxylase
by increasing the recruitment of RNA polymerase II and
histone acetylation at active promoters [51,52]. Nuclear
FGFR1 also physically interacts with Ribosomal S6 Kinase
isoform 1 (RSK1), a regulator of CBP and histone phos-
phorylation, and regulates its transcription activities
toward transcriptional regulators complexes [53]. The
Neurofilament-L, neuron-specific enolase microtubule associ-
ated protein-2 (MAP2) and c-jun genes are now identified
as target genes of nuclear FGFR1 [28,51]). Nuclear FGFR1
also potentiates cyclin D1 expression [28]. Nuclear FGFR1
thus regulates the expression of genes that are involved in
cell growth and differentiation. Interestingly, as for EGFR,
the transactivation of the target genes of nuclear FGFR1 is
not induced by stimulation of cell-surface FGFR1, suggest-
ing that the functions of a RTK at the plasma membrane
may differ from the ones inside the nucleus.
Initially, externally added FGF2, which accumulated in
the nucleus, was shown to correlate with stimulation of
ribosomal gene transcription, and activate transcription
in cell-free system [54-56]. More recently, in GST pull-
down assays, nucleolin, histone H1, Upstream binding
factor (UBF), an essential transcription factor for rRNA
transcription, and ribosomal protein P0 were found as
LMW FGF2 interacting partners [57]. Furthermore, LMW
FGF2 bound to UBF associates with rRNA genes and regu-
lates rRNA transcription both in vitro and in vivo [57].
Taken together, these results suggest a major role of
nuclear LMW FGF2 in the regulation of rRNA genes. In
addition, nuclear FGF2s regulate the transcription of
genes transcribed in mRNAs. Indeed, the phosphoglycerate
kinase 1 and 2 genes are regulated by nuclear FGF2 in a
promoter-specific manner [56]. Exogenously added LMW
FGF2 enter the nucleus and directly interacts with RSK2
[58], another isoform of RSK, in a cell cycle-dependent
manner. Nuclear LMW FGF2 may therefore potentiate the
RSK2 activities during the cell-cycle progression (see
below). Nuclear HMW FGF2s regulate the promoter activ-
ity of the IL-6 gene [59], and as FGFR1, they stimulate the
transcription of the Tyrosine Hydroxylase gene via cAMP
Response Element (CRE) sequences [51]. HMW nuclear
forms of FGF2 were also shown to physically interact with
the anti-apoptotic putative transcription factor FIF2 [60].
This interaction may be important for cell response to
stress.
Preliminary data suggested that nuclear CCN proteins
may regulate transcription. CCN2 activated transcription
in a cell-free system [4], and the CCN3 CT module was
found bound to a specific NFκB-like sequence in the pro-
moter of the Plasminogen Activator Inhibitor-2 (PAI-2) gene
[61]. Intriguingly, no functional activity for this binding
has been identified to date. We were unable to detect any
variation of the transcription level of the luciferase gene
cloned downstream human PAI-2  promoter sequences
when co-transfected with various nuclear forms of CCN3
(data not shown and [5]). However, we found that CCN3
was able to modulate transcription in other systems. We
used a single hybrid system in yeast, in which plasmids
expressing CCN3 recombinant proteins fused to the DBD
of the yeast Gal4 transcription factor. The recipient yeast
used for transient transfections contained the lacZ
reporter gene cloned downstream a promoter containing
Gal4-DBD binding sites. The results reported in Figure 3B
(Li et al. unpublished) indicated that under conditions in
which the full-length CCN3 protein showed no activity, a
CCN3 recombinant protein containing only IGFBP, VWC,
and TSP1 modules (NH24) (nomenclature depicted in
Figure 3A), induced a strong transcription transactivation.
Similar results were obtained with pACT2-derived con-
structs, which are known to express higher levels of
recombinant protein than pGADGH. The use of plasmids
expressing either individual domains or combinations of
domains, allowed us to establish that the VWC module of
CCN3 was responsible for the transactivation activity of
the recombinant proteins. Indeed, clones containing the
VWC module (NH3, NH23, and NH24) were positive in
the β-galactosidase assay, whereas NH2, NH4, NH5 and
NH45 were negative. The negative results observed with
NH35 (containing the VWC, TSP1 and CT modules) and
with the full-length CCN3 (NH25) raised the possibility
that the presence of the CT module was interfering with
the transactivating activity of the VWC module. These
results are in agreement with the transinhibitory effect of
the CT module that we have described in a recent report
[5].
In parallel, quantitative assays were performed in mam-
malian cells that confirmed the previous results obtained
in yeast. We used a pFA-CMV plasmid that expressed the
VWC module of CCN3 fused in frame with the DBD of
Gal4 (see [5] for the construction strategy). A six histidine
tag (6HIS) was added at the C-terminal part of the fusion
protein to allow immunological detection of the recom-
binant proteins (Figure 3C, lower panel left). For the
transactivation assays, cells were co-transfected with the
pFA-NH3 expression plasmid, the pFR-Luc reporter plas-
mid, in which the luciferase gene transcription was under
the control of 5 Gal4 binding sites, and a lacZ vector for β-
galactosidase normalization. The results established that
the VWC module could transactivate transcription in
mammalian cells in a dose-response manner (Figure 3C,
lower panel right). TADs are generally rich either in basic
amino acids, or in proline. CCN3 VWC module encom-
passes both several basic and proline residues (Figure 3A).
The IGFBP and TSP1 modules exert no significant effect
on transcription (not shown), whereas the CT moduleCell Communication and Signaling 2006, 4:7 http://www.biosignaling.com/content/4/1/7
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contains an inhibitory domain of transcription that is
stronger than the transactivation domain located in the
VWC module [5]. CCN3 nuclear forms may thus act as
transcriptional repressors [5]. Therefore, using a Gal4
reporter system, we showed that nuclear CCN3 forms
were able to modulate transcription in various eukaryotic
cells.
Interestingly, a similar situation has just been reported for
IGFBP proteins. Indeed, a strong transactivation domain
(TAD) was identified in the N-terminal part of IGFBP2,
IGFBP3 and IGFBP5 using a similar method [62], but this
TAD is masked by inhibitory domains located in the cen-
tral and carboxy-terminal parts of the protein [62].
IGFBP3 directly interacts with the Nuclear Retinoid X
Receptor (RXR) and was shown to regulate gene transcrip-
tion, using a RXR signaling reporter system [63,64].
IGFBP3 was indeed able to activate transcription via the
RXR-binding element (RXRE) and down-regulate tran-
scription via RAR-binding element (RARE), suggesting a
co-activator/repressor role for IGFBP3 in transcription
[63]. IGFBP3 interactions with RXR may lead to apoptosis
in certain conditions (see below).
Regulation of transcription by nuclear RTKs was also ini-
tially investigated using such single hybrid systems [65].
To date, functional TADs were identified for various RTKs
such as EGFR, ErbB2/HER2 and ErbB4/HER4 [39,46,47],
and it appears that nuclear GFs and RTKs regulate the tran-
scription of specific target genes. These observations open
interesting fields of investigation for the CCN proteins. At
the plasma membrane, CCN proteins are described as
docking proteins [7,11,12]. Similarly, in the nucleus,
CCN proteins may act as co-regulators, forming bridges
between transcription factors and the basal transcription
machinery. Along this line, the rpb7 subunit of RNA
polymerase II has been identified as a CCN3 partner in a
two-hybrid assay in yeast [34].
In summary, the above examples depict the variety of
mechanisms of action of nuclear GFs and RTKs on the reg-
ulation of transcription. Some of them (such as the EGF/
ErbB family, PRL, nucleolar FGF2) activate the transcrip-
tion of specific target genes by interacting with specific
transcription factors. Molecules like FGF1 and FGF2 can
also interact with general co-regulators such as CBP and
RSK proteins. Others (such as IGFBPs) seem to be able to
either activate or inhibit gene transcription depending on
their binding partners. They contain both TADs and TIDs
(transinhibitory domains).
Other actions in the nucleus
In addition to transcription, secreted proteins and RTKs
that are transported to the nucleus seem also to directly
regulate other important nuclear processes such as DNA
repair and RNAs processing. Promoting DNA repair by
ionization induces nuclear translocation of EGFR. This
translocation results in activation of DNA-dependent Pro-
tein Kinase (DNA-PK), an important effector for the repair
of DNA double-strand breaks [66]. These results suggest a
role for nuclear EGFR in DNA repair and cell survival after
irradiation.
Several studies suggest functions in the metabolism of the
different RNAs. For example, PTHrP has been detected in
the nucleus/nucleolus of a large variety of cells. PTHrP
contains in its N-terminal part a consensus sequence
found in numerous RNA binding proteins. PTHrP was
found to directly bind several types of RNAs, suggesting a
role in RNA metabolism [67].
Along the same line, nuclear FGF3 physically interacts
with the Nucleolar FGF3-Binding Protein (NoBP; a.k.a.
Ebp2p) and ribosomal protein S2 (rpS2) [68,69]. NoBP/
Ebp2p is required for pre-rRNA processing and is essential
for the synthesis of the 60S ribosomal subunit. RpS2 is a
component of the small sub-unit of the ribosome.
Nuclear FGF3 may therefore regulate ribosomal biogen-
esis.
HMW FGF2 (23 kDa) is associated with small nuclear
Ribonucleoproteins particles (snRNPs) by physical inter-
action with the Survival of Motoneuron (SMN) protein,
that functions as an assembly and recycling factor for the
splicing machinery [70]. SMN can be located in the cyto-
plasm and in the nucleus. HMW FGF2–23 co-localises
with SMN in the nucleus [70]. One of the subunits of the
splicing factor 3a was identified as a binding partner for
HMW FGF2–23 [71]. Electron microscopy studies
revealed co-localization of FGFR1 with snRNPs in the
nucleus of differentiating neurons but not proliferating
neurons in cultures [51]. Therefore, nuclear FGF2/FGFR1
may be involved in mRNA processing during neuronal
differentiation. Moreover, in as much as FGF2 is a neuro-
trophic factor for motoneurons (see below) and as SMN is
deficient in patients with spinal muscular atrophy, a neu-
rodegenerative disease, the FGF2-SMN complexes may be
important for survival or degeneration of motoneurons.
The nuclear activities of secreted factors and RTKs cited
above are summarized in Figure 2.
Regulation of cell proliferation & differentiation
Cell proliferation
Transcriptional targets and nuclear partners of nuclear
GFs and RTKs are often involved in cell proliferation. For
example, Cyclin D1, c-jun, c-Myc, c-fos, b-Myb, STAT3. It
therefore seems that nuclear GFs and RTKs are linked to
cell cycle progression and proliferation. In fact, correla-
tion between nuclear localization of GFs/RTKs and prolif-Cell Communication and Signaling 2006, 4:7 http://www.biosignaling.com/content/4/1/7
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eration has been established in various cell types a long
time ago before the mechanisms of action were elucidated
[72-75].
Nuclear EGFR has been detected for years in a variety of
cell lines, normal and pathological tissues. Nuclear local-
ization of EGFR was correlated with a high proliferative
state in various tissues such as human placenta, human
normal mouth mucosa, uterus of pregnant mice, or rat
regenerative liver [46,76]. In this latter case, EGFR was
indeed detected only in the nuclei of dividing hepato-
cytes, not in quiescent ones. Along the same line, in pri-
mary breast cancers, a positive correlation was established
between high levels of nuclear EGFR and expression of
cyclin D1 and Ki-67, two markers of active proliferation
[46,77]. According with a role in cell proliferation, the
translocation of ErbB1-EGF/Tumor Growth Factor-α
(TGF-α) complexes to the nucleus seems to precede DNA
replication [78,79]. Mutations introduced in the NLS of
the EGFR-ligand SwGF result in the loss of its mitogenic
activities.
Enhancement of c-jun expression by nuclear FGFR1, acti-
vation of rRNA transcription by nuclear FGFR1 and FGF2,
and stimulation of DNA synthesis by nuclear FGF1
[25,80] are in favor of a role of nuclear FGFs/FGFRs in cell
proliferation. It was indeed shown in various cell types
that the accumulation in the nucleus of FGFs and FGFRs
mostly takes place transiently during the G1 phase of the
cell cycle and stimulates cell proliferation
[17,28,54,55,81]. For instance, nuclear FGF2 maintains
the RSK2 protein active during G1 phase, and FGF2
mutated in its sites of interaction with RSK2 loses 50% of
its mitogenic activity [58]. Similarly, deletion of the NLS
region in FGF1 considerably reduces FGF1 mitogenic
activities [80]. Nuclear FGF2/FGFR1 may participate in
the control of glial cell proliferation both in the embryo
and also in the adult. FGF2 was indeed detected in the
nucleus of rat brain astrocytes in vivo and in vitro, as well
as in human astrocytes in culture [82,83]. FGF2 was
observed in the nucleus of proliferating astrocytes, but
was localized only in the cytoplasm in quiescent astro-
cytes [83]. FGFR1 was transiently detected in the nucleus
of astrocytes during the G1 phase of the cell cycle. Glioma
cells constitutively express high levels of nuclear FGF2 and
FGFR1. Furthermore, increase in nuclear FGF2 and FGFR1
levels were observed after brain lesions and were associ-
ated with scar formation by proliferating astrocytes.
On the contrary to the above examples, nuclear FGF3
inhibits DNA synthesis and proliferation [84]. Interest-
ingly, the nuclear functions of FGF3 are in opposition to
that of secreted FGF3, which stimulates cell growth and
transformation. Nuclear FGF3 acts through a physical
interaction with NoBP and rpS2 proteins [68,69]. NoBP
expression is associated with cell proliferation. It appears
that nuclear FGF3 counteracts NoBP activities [68]. Simi-
larly, rpS2 has been associated with up-regulation of pro-
liferation and cancer cell growth. As for NoBP, FGF3 may
also block rpS2 activities. FGF3 thus may inhibit cell pro-
liferation by interfering with the ribosomal biogenesis.
Nuclear PTHrP is able to regulate both cell growth and cell
death. Indeed, PTHrP entry into the nucleus induces pro-
liferation of vascular smooth muscle cells [85], and nucle-
olar localization of PTHrP protects chondrocytes against
apoptosis induced by serum starvation [86].
These few examples underline the variety of action of the
nuclear GFs/RTKs on the cell cycle, by up-regulating or
down-regulating cell proliferation and cell death.
Cell differentiation during embryonic development and 
adult life
Nuclear FGF2 and FGFRs are involved in nervous system
development. FGF2 is expressed in glial cells and certain
neuronal populations. FGF2 acts as a neurotropic factor
for a variety of central and peripheral neuronal types, act-
ing either as a mitogen or a differentiating factor. It can
promote neuronal survival, neuritogenesis and synaptic
transmission. During rat nervous system development,
both LMW and HMW FGF2s have been detected in the
nuclear fraction of brain extracts [51]. More precisely, it
was shown that FGF2 accumulated in the nucleus of cere-
bellar neurons as axonal growth took place. Once the syn-
aptic connections were established, FGF2 nuclear labeling
disappeared [87], though a recent publication reported
that nuclear FGF2 was still detectable in certain neurons of
adult mouse cerebellum [88]. FGFR1 has also been
observed in the nucleus of developing rat brain cells and
of a variety of neuronal cell lines. Treatments with stimuli
such as Bone Morphogenic Protein 7 (BMP7) and cAMP,
that induce neuronal-like differentiation, provoke nuclear
accumulation of FGF2 and FGFR1 in various cell lines in
culture. Moreover, nuclear FGFR1 is able to induce neuro-
nal-like differentiation in a variety of neuronal cell lines.
For example, FGFR1 expression mediates cAMP-induced
cell cycle exit, neurite outgrowth and induction of neuron-
specific genes in human neuronal progenitor cells
(HNPCs) [51,81]. Interestingly, FGFR1 forms that remain
at the plasma membrane fail to induce neuronal differen-
tiation, and even block cAMP-induced neuronal differen-
tiation [51,81]. Therefore, nuclear FGFR1 appears to be
important for neuronal differentiation in the central nerv-
ous system. Increase in LMW and HMW FGF2s levels are
detected in neurons and glial cells in peripheral nerves
after injury. LMW, HMW FGF2s and FGFR1 accumulate in
the nucleus of primary neonatal sympathetic neurons
transiently transfected in culture [89]. In summary, it
seems that nuclear FGF2s/FGFR1 are involved in neuronalCell Communication and Signaling 2006, 4:7 http://www.biosignaling.com/content/4/1/7
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differentiation in the central and peripheral nervous sys-
tems, and residual levels still detectable in adult, could be
reactivated after lesion.
FGF2 and FGFRs also play critical roles during bone mor-
phogenesis. Prostaglandins (PGs) are also involved in
bone formation and resorption. It was very recently
reported that PGF2α induced FGF2 nuclear translocation
in rat osteoblasts and stimulated FGF2/FGFR2 internaliza-
tion via clathrin-independent vesicles [90,91]. FGF2/
FGFR2 complexes were subsequently found at the nuclear
pore level, where they co-localized with IMPβ, suggesting
a role for nuclear FGF2-FGFRs in bone formation.
The above examples reporting cellular functions for
nuclear forms of secreted molecules often come from in
vitro models. Like FGFR1 in NPCs, in Sertoli cells FGFR2
is detected in the nucleus of cells that withdraw from the
cell cycle. Recently, the analysis of fgf9-/- mice revealed that
FGFR2 nuclear localization correlated with male sex deter-
mination in early gonads [92]. Nuclear FGFR2 coincided
with the initiation of expression of the Sry gene, which
determines the sex of the gonad, differentiating cells into
Sertoli cells.
In adult, HMW FGF2s may be involved in wound healing.
Pintucci and colleagues reported in a recent publication
that, in an experimental injury model of vascular aortic
smooth muscle cells, Platelet Derived Growth Factor
(PDGF) rapidly induced expression of HMW FGF2, which
accumulated in cell nuclei and nucleoli [93]. In contrast,
PDGF did not induce LMW FGF2 expression, suggesting a
specific role of nuclear HMG FGF2 in vascular remodeling
after injury. Along the same line, in an in vitro model of
wound healing using endothelial cells, VEGF was found
to be rapidly internalized and specifically translocated to
the nuclei of cells localized at the edges of the wound [94].
This phenomenon was accompanied in these cells by an
increase in several wound healing related molecules such
as integrin β3, factor VIII and tissue plasminogen activa-
tor, suggesting that VEGF nuclear accumulation may be
involved in coagulation and fibrinolysis processes during
repair after injury. VEGF was also endocytosed in cells
away from the wound, but in this case, it was not
imported to the nucleus, and no accumulation of repair
related proteins was observed [94].
In summary, as for the classical extracellular pathways,
nuclear GFs and RTKs can differentially regulate the cell
proliferation and differentiation of target cell types, tis-
sues and organs during embryogenesis. In adult, they may
be involved in tissue repair after injury.
Cancer
GFs and RTKs were detected in the nucleus of cancer cells
a long time ago. In accord with their roles in cell cycle pro-
gression and proliferation, it is tempting to speculate that
nuclear secreted factors and plasma membrane RTKs may
sometimes be oncogenic, for example because of the
deregulation of their shuttling between the cytoplasm and
the nucleus in cancer cells. Some of their target genes or
nuclear partners, such as Cyclin D1, c-jun, c-Myc, c-fos, b-
Myb, COX2, STAT3 are known as key players in oncogen-
esis when they are deregulated. Overexpression of such
genes can induce tumorigenesis. Recent studies showed
that nuclear localization of secreted factors and RTKs in
cancer cells is often associated with poor prognosis of sur-
vival. Furthermore a growing body of evidence suggests
that nuclear secreted proteins and cell surface receptors
are involved in tumor progression.
Proliferation of cancer cells and tumor progression
PTHrP is expressed in breast epithelium and participates
in normal mammary gland development and function.
Most breast cancers secrete high level of PTHrP. Secreted
PTHrP is in fact a prohormone that is cleaved into multi-
ple peptides. The best characterized fragment (N-PTHrP)
acts via cell surface PTHR1. The midregion of PTHrP
(midPTHrP) binds another transmembrane receptor, is
internalized and migrates to the nucleus via a bipartite
NLS-dependent pathway [95]. High levels of MidPTHrP
were detected in the nuclei of human non invasive MCF-
7 and invasive MDA-MB231 breast cancer cells, but not in
the nuclei of Hs578Bst non-tumor breast myoepithelial
cells [95]. MidPTHrP increased proliferation of MCF-7
and MDA-MB231 cells, whereas it did not influence
Hs578Bst growth [95]. A midPTHrP form that lacks the
NLS and that remains in the cytoplasm did not increase
proliferation of MCF-7 and MDA-MB231 cells [95], sug-
gesting a role for nuclear PTHrP in breast cancer progres-
sion. Along the same line, ErbB4 overexpression in MCF-
7 cells resulted in nuclear translocation of cleaved ErbB4,
increased proliferation and anchorage-independent
growth, and estrogen response element-mediated tran-
scriptional activity [96].
Cancer cells frequently express HMW FGF2s. Increased
levels of HMW FGF2s was observed during the transfor-
mation process in vitro [97,98]. Overexpression of HMW
FGF2s leads to immortalization of primary cells in culture
and allowed proliferation of immortalized cells in low-
serum to achieve high cell density [99-101]. Cell-contact
inhibition and mitotic activation were associated with
nuclear accumulation of both LMW and HMW FGF2s in
glioma cells [83]. Nuclear HMW (24 kDa) FGF2 facilitates
cell survival in vitro and also during the establishment of
metastases in vivo [102]. Taken together, these results sug-
gest that HMW FGF2s might be involved in tumor pro-Cell Communication and Signaling 2006, 4:7 http://www.biosignaling.com/content/4/1/7
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gression. In some cases, the detection of high levels of
HMW FGF2 in cell nuclei was even correlated with poor
prognosis for patient survival (see below). FGFR1 accu-
mulated in the nucleus in parallel with FGF2. Nuclear
FGFR1 has been detected in both rapidly proliferating
human medulloblastoma TE671 cells and slower prolifer-
ating glioma SF763 cells [103]. Furthermore, stable trans-
fection of SF-763 glioma cells with either FGFR1 or HMW
FGF2 resulted in nuclear localization of the receptor and
the growth factor and in increased proliferation [51].
Along the same line, in breast tumors, FGF1 and FGFR3
are predominantly localized in the nuclei of epithelial
cells, whereas they showed both nuclear and cytoplasmic
localization in normal breast epithelium [104].
The CCN3 protein is detected in the nuclei of various can-
cer cell types, and this nuclear form of CCN3 is sometimes
truncated, deprived of its amino-terminal part ([32,34]
and unpublished data). The full-length secreted CCN3
exerts inhibitory effects on the proliferation of various
human cancer cell lines, whereas an amino-truncated
form deprived of the secretory peptide signal, was show-
ing transforming activities on primary cells in culture
(reviewed in [105-107]). We recently showed that such
truncated forms of CCN3 are predominantly localized in
the nucleus [5]. Therefore, the proliferation status of cells
that express CCN3 may be the result of a subtle balance
between the level of full-length secreted forms and
nuclear amino-truncated forms of CCN3. A deregulation
in this balance may result in tumorigenic events.
IL-1α is a pleiotropic cytokine involved in immune and
inflammatory response, as well as in hematopoiesis. Fur-
thermore, Il-1α stimulates growth of malignant cells such
as gastric carcinoma cells, B-lymphoblasts, acute myelog-
enous leukemia cells, and Kaposi sarcoma cells. Secreted
IL-1α is generated by proteolytic cleavage of an intracyto-
plasmic polypeptidic precursor by calpain protease.
Whereas the carboxy-terminal part of the precursor is
secreted and binds transmembrane IL-1 receptor, its N-
terminal part (IL-1α propiece) is translocated to the
nucleus via NLS-dependent mechanism [108]. Independ-
ently, secreted IL-1α bound to its transmembrane receptor
can be internalized and also transported to the nucleus via
a NLS located in the receptor. Interestingly, when stably
expressed in glomerular mesangial cells, IL-1α propiece
was able to induce anchorage-independent growth in vitro
and very aggressive tumors in vivo when the IL-1α prop-
iece-expressing cells were re-injected in Nude mice [108],
suggesting that nuclear IL-1α propiece can act as an onco-
genic protein.
Association with bad prognosis, poor survival and 
resistance to anti-cancer therapies
Receptors of the EGFR/ErbB family have been detected in
the nuclei of various human cancer types such as sarcoma,
adrenocortical carcinoma, uterine cervix lesions, mouth
cancer, and breast cancer. Several reports revealed positive
correlations between nuclear localization of ErbB recep-
tors and expression of target genes and nuclear partners in
cancer cells: for example, ErbB2/HER2 and COX2 in
choloangiocarcinoma, colon cancer and breast cancer
[47]; also EGFR and cyclin D1/iNOS/STAT3 in breast can-
cers ([48], reviewed in [109]). Interestingly, the COX2 and
iNOS enzymes produce inflammatory prostaglandins and
nitric oxide respectively, molecules that emerge as targets
for chemoprevention and chemotherapy. COX2 contrib-
utes to increased anti-apoptotic, pro-angiogenic, and met-
astatic potential in cancer cells, and deregulation of COX2
expression was associated with tumor progression, sug-
gesting that COX2 overexpression induced by nuclear
ErbB2/HER2 in cancer cells may be a marker of bad prog-
nosis. Along the same line, the study of a large panel of
breast carcinomas and oral squamous cell carcinomas
established an inverse correlation between nuclear EGFR
and patient survival, suggesting that nuclear EGFR accu-
mulation may be indicative of poor clinical outcome
[77,110]. This observation may, in part, be due to
increased proliferative capacity in cancer cells that exhibit
nuclear EGFR. Nuclear ErbB4/HER4 was also associated
with poor prognosis in breast cancer, in contrast to mem-
brane bound ErbB4/HER4 [96].
Interestingly, in human bronchial and breast tumor cells,
blocking the ionization-induced nuclear import of EGFR
by the use of anti-EGFR antibodies increased radio-sensi-
tivity of treated cells, by sequestering DNA-PK in the cyto-
plasm, complexed to EGFR [111]. Preclinical studies
showed that anti-EGFR antibodies enhanced anti-tumor
effects of irradiation, suggesting that combining immuno-
therapy to radiotherapy and chemotherapy may be suc-
cessful in anti-tumor therapies for cancers exhibiting
EGFR nuclear localization [111].
EGFR does not only bind extracellular EGF, but also
Heparin Binding Epidermal Growth Factor-like (HB-
EGF). HB-EGF can be internalized and transiently translo-
cated to the nucleus during late G1 and S phases of the cell
cycle. Binding and triggering nuclear export of Promyelo-
cytic Leukemia Zinc Finger protein (PLZF), a transcrip-
tional repressor of the cyclin A gene, HB-EGF promotes
cell cycle progression into the S phase [112]. HB-EGF is
generated by proteolytic cleavage of the transmembrane
precursor proHB-EGF. The intracytoplasmic part of
proHB-EGF can also migrate to the nucleus, and thereby
alters cell cycle in EGFR-independent manner [113]. Full-
length proHB-EGF was also detected in the nuclei ofCell Communication and Signaling 2006, 4:7 http://www.biosignaling.com/content/4/1/7
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human TCCSUP bladder cancer cells, and correlated with
poor prognosis in bladder cancers [114,115]. Further-
more, Reactive Oxygene Species (ROS), metabolites that
are overproduced in cancer cell as a result of transforma-
tion process, induced nuclear export of proHB-EGF in
TCCSUP cells. Exported proHB-EGF was then cleaved by a
metalloproteinase, HB-EGF was secreted in the extracellu-
lar compartment, where it activated transmembrane
EGFR, resulting in stimulation of cell proliferation and
partial protection from cisplatin and oxidative stress-
induced apoptosis [115]. These results support the idea of
an autocrine loop leading to cell proliferation and protec-
tion from apoptotic stimuli in bladder cancer cells [115].
Taken together, these results show that various nuclear
forms of HB-EGF can promote cancer progression by dis-
tinct mechanisms.
In human astrocytic tumors cells, high levels of nuclear
HMW FGF2s have been correlated with poor prognosis
[116]. Furthermore, overexpression of HMW FGF2s has
been observed in various human cancer cells of patients
resistant to radiotherapy. It has even been shown that
overexpression of HMW FGF2s in HeLa cells protected
them from irradiation by directly up-regulating the
expression of the DNA-PKcs, which encodes one of the
sub-unit of the DNA-repair DNA-PK enzyme [117]. As for
EGF and HB-EGF, targeting nuclear HMW FGF2s may gen-
erate new anti-cancer therapies for patients resistant to
classical protocols.
Promotion of apoptosis of cancer cells
IGFBPs bind Insulin-like Growth Factors (IGFs) in the
extracellular compartment and modulate their mitogenic
effects, but IGFBPs can also act on cell proliferation and
apoptosis via IGF-independent mechanisms. IGFBPs
modulate proliferation and survival of various tumor cell
types including osteosarcoma cells. The IGFBP3 protein,
which is encoded by a tumor suppressor gene, exhibits
anti-proliferative and pro-apoptotic functions, both in
IGF-dependent and IGF-independent pathways. IGFBP3
has been detected in the nuclei of human lung, breast and
prostate cancer cells. IGFBP3 induces apoptotic cell death
in human colon carcinoma cells and breast cancer cells.
Furthermore, nuclear IGFBP3 is able to enhance apoptosis
in U-2 OS osteosarcoma cells, in a caspase-dependent
mechanism [43]. In agreement with a proapototic role of
nuclear IGFBP3, endogenous IGFBP3 is detected only at
very low levels in the nuclei of U-2 OS cells [43]. Since a
proteasome-dependent degradation of nuclear IGFBP3
has been described in U-2 OS cells, IGFBP3 may therefore
be subject to a rapid turn over by proteolysis in the
nucleus of cancer cells [43]. IGFBP3 and RXR ligands have
additive effects on apoptosis of human prostate cancer
cells both in vitro and in vivo [118]. RXR α is even essential
for apoptotic functions of IGFBP3. In as much as nuclear
IGFBP3 is able to modulate transcription via RXR binding
sites (see above), nuclear IGFBP3 may cooperate with
retinoic receptors to induce gene transcription leading to
apoptosis in cancer cells [63].
Though Il-1α propiece has been described as an onco-
genic protein (see above), more recently, nuclear IL-1α
propiece was shown to induce apoptosis in a large panel
of cancer cell lines of several origins such as lung, colon,
central nervous system, blood, skin, kidney, breast, ovary,
whereas it did not in non malignant primary cells [119].
IL-1α propiece co-localized in the nucleus with several
components of the spliceosome machinery and provoked
a decrease in anti-apoptotic alternate form of Bcl-X. As a
consequence a change in the balance between anti- and
pro-apoptotic forms of Bcl-X occurs in favor of the pro-
apoptotic form [119]. These data suggest that nuclear IL-
1α propiece may induce apoptosis in cancer cells by mod-
ifications in RNA processing. Taken together, these results
underline a dual role for nuclear IL-1α depending on cel-
lular context.
In summary, nuclear localization of GFs and RTKs of the
FGF and EGF/Erb families in cancer cells seems to be asso-
ciated with a bad prognosis for patient survival. At least
two reasons can explain this correlation. The first one is
their role in the promotion of cancer cell proliferation and
transformation, which favors tumor progression. The sec-
ond one is in the resistance to radiotherapy that they
appear to induce because of their potential role in DNA
repair. It is worth noting that, in agreement with its role in
cell proliferation, FGF1 has been detected in the nucleus
of certain cells within inflammatory arthritic joints in the
synovium from patients with rheumatoid arthritis [120].
This disease is characterized by massive proliferation of
synovial connective tissues and invasive destruction of
periarticular bone and cartilage. These data suggest a role
for nuclear GFs in pathologies other than cancers. By con-
trast, inhibiting cell proliferation and promoting apopto-
sis of cancer cells, other secreted factors such as IGFBPs
may be markers of good prognosis.
Conclusions and future considerations
The nuclear localization of secreted proteins and plasma
membrane receptors has been known for more than 15
years, but their nuclear translocation and functions has
remained largely unknown until recently. The number of
studies describing diverse physiological functions for
nuclear ligands and their receptors has grown rapidly in
the literature since 2004/2005. Though the discovery of
transcriptional activity of nuclear EGFR on cyclin D1 pro-
moter in 2001 by Lin and colleagues in Nature Cell Biol-
ogy [46] lead to a comment entitled "EGF receptors as
transcription factors: ridiculous or sublime?" in the same
volume [121], the physiological functions of nuclearCell Communication and Signaling 2006, 4:7 http://www.biosignaling.com/content/4/1/7
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secreted ligands and their receptors could no longer be
subject to controversy.
The classical view on the modes of action of the secreted
molecules has evolved during the last decade. It appears
today that GFs act on cells by several distinct mechanisms.
Activated RTKs by ligand binding can induce signals
inside the cell through several second messenger path-
ways depending on the cellular context. In addition,
receptor-bound GFs can be internalized by endocytosis
and translocated to the nucleus (Figure 4). FGF1, FGF2
and FGF3 are known to act both extracellularly and intra-
cellularly. Although FGF2 was shown to activate rRNA
transcription in both ways, secreted FGF3 and nuclear
FGF3 exhibit opposite functions on cell proliferation. The
case of CCN3 resembles the one described for FGF3.
Possible mechanisms of action for secreted protein function in cell proliferation, either by intracellular second messengers  pathways or by nuclear import Figure 4
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Therefore, it appears that secreted forms and nuclear
forms of GFs can act either in concert or in opposition
(Figure 4).
In the nucleus, secreted factors and receptors regulate the
transcription of specific target genes by direct binding to
transcription factors and general coregulators. They could
also be involved in other processes such as DNA replica-
tion, DNA repair and RNA metabolism. Their target genes
and protein partners often become oncogenic when they
are deregulated. Therefore alteration of nuclear shuttling
of secreted molecules and cell surface receptors may result
in the development of pathologies of cell proliferation. A
growing body of evidence correlates nuclear localization
of GFs and RTKs with cancer progression in various organs
in human. The presence of some of them in the nucleus
even seems to provoke resistance to radiotherapy. Target-
ing nuclear import of the secreted molecules and their
receptors opens new areas for investigation for future anti-
cancer therapies.
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